Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome

Journal of Allergy and Clinical Immunology

Volumn 134, Issue 1, 2014, Pages

  Kracker, Sven ^a,b   Curtis, James ^c   Ibrahim, Mohammad A A ^d   Sediva, Anna ^e   Salisbury, Jon ^d   Campr, Vit ^e   Debré, Marianne ^a   Edgar, J David M ^f   Imai, Kohsuke ^g   Picard, Capucine ^a,b,h   Casanova, Jean Laurent ^b,h,i   Fischer, Alain ^a,b   Nejentsev, Sergey ^c   Durandy, Anne ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Inserm U1163   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^h IMAGINE INSTITUTE   (France)

ⁱ ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN;

B CELL LYMPHOMA; CASE REPORT; CLINICAL FEATURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LETTER; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; SYNDROME; ADOLESCENT; ADULT; COMPLICATION; FEMALE; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; IMMUNE DEFICIENCY; IMMUNOLOGY; MUTATION; PATHOLOGY;

ADOLESCENT; ADULT; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOMA, B-CELL; MALE; MUTATION;

EID: 84903746318     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.02.020     Document Type: Article

References (11)

1. I. Angulo, O. Vadas, F. Garcon, E. Banham-Hall, V. Plagnol, and T.R. Leahy et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage Science 342 2013 866 871
2. C.L. Lucas, H.S. Kuehn, F. Zhao, J.E. Niemela, E.K. Deenick, and U. Palendira et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency Nat Immunol 15 2014 88 97
3. S. Kang, A. Denley, B. Vanhaesebroeck, and P.K. Vogt Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase Proc Natl Acad Sci U S A 103 2006 1289 1294
4. S. Sander, D.P. Calado, L. Srinivasan, K. Kochert, B. Zhang, and M. Rosolowski et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis Cancer Cell 22 2012 167 179
5. R.C. Rickert New insights into pre-BCR and BCR signalling with relevance to B cell malignancies Nat Rev Immunol 13 2013 578 591
6. J. Zhang, V. Grubor, C.L. Love, A. Banerjee, K.L. Richards, and P.A. Mieczkowski et al. Genetic heterogeneity of diffuse large B-cell lymphoma Proc Natl Acad Sci U S A 110 2013 1398 1403
7. H.K. Webb, H. Chen, A.S. Yu, S. Peterman, L. Holes, and B. Lannutti et al. Clinical pharmacokinetics of CAL-101, a p110{delta} isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies Blood (ASH Ann Meet Abstr) 116 2010 1774A
8. B. Neven, E. Mamessier, J. Bruneau, S. Kaltenbach, D. Kotlarz, and F. Suarez et al. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency Blood 122 2013 3713 3722
9. C. Cunningham-Rundles How I treat common variable immune deficiency Blood 116 2010 7 15
10. A. Atra, J.D. Imeson, R. Hobson, M. Gerrard, I.M. Hann, and O.B. Eden et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol Br J Cancer 82 2000 1396 1402
11. W.T. Shearer, H.M. Rosenblatt, R.S. Gelman, R. Oyomopito, S. Plaeger, and E.R. Stiehm et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study J Allergy Clin Immunol 112 2003 973 980